Paragon 28, Inc. (FNA)
(Delayed Data from NYSE)
$6.64 USD
-1.67 (-20.10%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $6.64 0.00 (0.00%) 6:04 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
FNA 6.64 -1.67(-20.10%)
Will FNA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for FNA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FNA
Nevro (NVRO) Reports Q2 Loss, Misses Revenue Estimates
Paragon 28 (FNA) Expands Syndesmotic Repair Line With New Launch
FNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Paragon 28, Inc. (FNA) Moves 16.2% Higher: Will This Strength Last?
Sensus Healthcare, Inc. (SRTS) Q4 Earnings and Revenues Top Estimates
Paragon 28 (FNA) BEAST Cortical Fibers Launch Boosts Biologics
Other News for FNA
Paragon 28 falls -22.9%
Buy Rating for Paragon 28: Strong Growth and Strategic Initiatives Signal Market Share Expansion in Orthopedics
Paragon 28 price target lowered by $3 at Piper Sandler, here's why
Analysts Offer Insights on Healthcare Companies: Paragon 28 (FNA), ADMA Biologics (ADMA) and Veracyte (VCYT)
Buy Rating Affirmed for Paragon 28 Amid Revenue Growth and Positive EBITDA Outlook